Bivalirudin Found to Be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention - Mount Sinai

Mount Sinai survey could alteration the attraction people for hundreds of thousands of patients, redeeming lives and preventing complications

Bivalirudin is simply a safer and much effectual anticoagulant than heparin for treating patients with the astir superior benignant of bosom attacks who acquisition urgent percutaneous coronary involution (PCI), and tin little the hazard of decease oregon large bleeding by 31 percent.

These are findings from a caller survey led by researchers from the Icahn School of Medicine astatine Mount Sinai. This is the archetypal large-scale objective proceedings to comparison the 2 anticoagulants astir wide utilized aft PCI, and shows bivalirudin fixed with a two- to four-hour high-dose infusion importantly reduces death, large bleeding, and thrombosis erstwhile compared with heparin.

The results were announced Sunday, November 6, successful a Late Breaking Clinical Trial presumption astatine the American Heart Association’s Scientific Sessions (AHA 22) successful Chicago, and published successful The Lancet. This enactment could person wide implications, changing the attraction people for hundreds of thousands of patients crossed the satellite who acquisition a large blockage of a bosom artery, a information known arsenic ST-segment elevation myocardial infarction oregon STEMI. It is the astir superior benignant of bosom attack.

“For the archetypal time, this survey identifies the champion and safest attraction people for patients undergoing stenting to dainty a STEMI bosom attack,” says co-Principal Investigator Gregg W. Stone, MD, Director of Academic Affairs for the Mount Sinai Health System and Professor of Medicine (Cardiology), and Population Health Science and Policy, astatine Icahn Mount Sinai. “Compared with heparin, bivalirudin positive a abbreviated infusion substantially improved the likelihood of surviving a STEMI and reduced the 2 astir feared complications—major bleeding and stent thrombosis.”

In the “BRIGHT-4” trial, patients with STEMI bosom attacks underwent “primary PCI”—an exigency stenting process to sphere bosom musculus function. Patients necessitate anticoagulant therapy during this minimally invasive process to successfully unfastened the blocked bosom artery and forestall aboriginal humor clots from forming and causing different bosom attack.

The astir communal anticoagulant utilized during superior PCI is heparin. However, its effects tin beryllium somewhat unpredictable, starring to higher-than-desirable rates of bleeding and humor clots. Bivalirudin is simply a newer anticoagulant that has much predictable “blood thinning” effects. Heparin and bivalirudin person been compared successful six anterior ample randomized trials successful patients with STEMI, but successful those studies, they were administered with varying regimens and inheritance therapies. This caller probe evaluates the 2 astir wide utilized regimens of heparin and bivalirudin, which person ne'er been straight compared with each different successful an adequately sized trial.

Dr. Stone on with Yaling Han, MD, PhD, of Shenyang Northern Hospital successful Shenyang, China led a squad of researchers to analyse 6,106 patients enrolled successful the survey crossed 87 sites successful China betwixt February 2019 and April 2022. All underwent superior PCI for STEMI treatment, astir each with a process that utilized the radial artery successful the wrist to people the blocked bosom artery. Patients were randomized to person the 2 astir wide utilized regimens of heparin and bivalirudin, which anterior studies person shown to beryllium the safest and astir effective. One radical received heparin alone, administered done an IV. The different radical received bivalirudin done an IV, followed by a high-dose IV infusion for 2 to 4 hours aft the procedure.

Investigators followed patients for 30 days pursuing the procedure, the timeframe successful which STEMI patients are astatine highest hazard for adverse events. The superior extremity of the survey was to comparison the occurrence of all-cause mortality oregon large bleeding. Researchers recovered that 4.4 percent of patients treated with heparin died oregon had a large bleed wrong 30 days, compared to 3.1 percent of patients treated with bivalirudin. Overall, the bivalirudin radical had a 31 percent simplification successful the complaint of decease oregon large bleeding compared with patients successful the heparin group—a highly statistically important reduction.

Then researchers past looked astatine the circumstantial incidence of decease unsocial and large bleeding unsocial betwixt the groups. They recovered that deaths were reduced from 3.9 percent successful heparin-treated patients to 3.0 percent successful bivalirudin-treated patients. Severe bleeding besides was reduced from 0.8 percent successful the heparin radical to 0.2 percent successful the bivalirudin group. Both of these differences were statistically significant.

They besides analyzed the complaint of stent thrombosis—a complication that happens erstwhile the vas abruptly closes arsenic the effect of a humor clot that typically leads to a 2nd bosom onslaught oregon death. This was besides little successful the bivalirudin radical astatine 0.4 percent compared with 1.1 successful the heparin group, again a statistically important reduction.

“These results are dramatic,” Dr. Stone said. “The elemental determination to usage bivalirudin during superior PCI successful patients with bosom attacks, which is present generic and frankincense inexpensive, tin prevention hundreds of thousands of lives per twelvemonth and forestall large bleeding and stent thrombosis compared with heparin.”

The BRIGHT-4 proceedings was an researcher sponsored and organized trial. The proceedings was funded by the Chinese Society of Cardiology Foundation (CSCF2019A01) with a probe assistance from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Mount Sinai Heart is 1 of the nation’s apical 6 hospitals successful Cardiology/Heart Surgery

Mount Sinai Heart is among the apical 6 successful the federation for cardiology and cardiac country according to U.S. News & World Report.  Newsweek’s “The World’s Best Specialized Hospitals” ranks Mount Sinai Heart arsenic No. 1 successful New York and No. 4 globally.

---

About the Mount Sinai Health System

Mount Sinai Health System is 1 of the largest world aesculapian systems successful the New York metro area, with much than 43,000 employees moving crossed 8 hospitals, implicit 400 outpatient practices, astir 300 labs, a schoolhouse of nursing, and a starring schoolhouse of medicine and postgraduate education. Mount Sinai advances wellness for each people, everywhere, by taking connected the astir analyzable wellness attraction challenges of our clip — discovering and applying caller technological learning and knowledge; processing safer, much effectual treatments; educating the adjacent procreation of aesculapian leaders and innovators; and supporting section communities by delivering high-quality attraction to each who request it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers broad wellness attraction solutions from commencement done geriatrics, leveraging innovative approaches specified arsenic artificial quality and informatics portion keeping patients’ aesculapian and affectional needs astatine the halfway of each treatment. The Health System includes astir 7,300 superior and specialty attraction physicians; 13 joint-venture outpatient country centers passim the 5 boroughs of New York City, Westchester, Long Island, and Florida; and much than 30 affiliated assemblage wellness centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving precocious "Honor Roll" status, and are highly ranked: No. 1 successful Geriatrics and apical 20 successful Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 successful Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s champion successful respective pediatric specialties. The Icahn School of Medicine astatine Mount Sinai is 1 of 3 aesculapian schools that person earned favoritism by aggregate indicators: It is consistently ranked successful the apical 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and apical 20 successful the federation for National Institutes of Health backing and apical 5 successful the federation for galore basal and objective probe areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital arsenic No. 1 successful New York and successful the apical 5 globally, and Mount Sinai Morningside successful the apical 20 globally.

For much information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.